Pediatrics · Medical Literature
Impact of a multiplex respiratory PCR panel on antibiotic stewardship in hospitalized pediatric pneumonia: a randomized clinical trial.
Abstract
We aimed to evaluate whether the FILMARRAY® Pneumonia Panel (FAPP) added to standard care could effectively guide antibiotic prescriptions in hospitalized pediatric patients with infectious pneumonia. In this single-center, open-label, parallel-group randomized controlled clinical trial, we enrolled hospitalized children (28 days to 18 years old) diagnosed with infectious pneumonia. Participants were randomized to standard care only (control) or to added FAPP (intervention group). The primary outcome was the proportion of patients with antibiotic change within 72 h. Between December 8, 2021, and February 16, 2023, we enrolled 315 patients (157 in the intervention group and 158 in the control group). Pathogens were detected in 86.6% (32.7% bacterial, 56.5% viral, and 10.9% atypical) via FAPP, which may encompass colonizing organisms due to its enhanced sensitivity. The primary outcome was comparable between the intervention and control groups (51.6%, 81/157, versus 49.4%, 78/158; P = 0.693). However, key exploratory secondary outcomes demonstrated significant improvements in the intervention group: total frequency of changes in antibiotic and antiviral agents based on pathogen results (47.8%, 75/157, versus 25.3%, 40/158; P < 0.001) and proportion of patients with antibiotic de-escalation within 72 h (14.6%, 23/157, versus 1.9%, 3/158; P < 0.001). Integrating FILMARRAY® into pediatric pneumonia clinical management did not significantly boost initial overall antibiotic modification rates. However, exploratory analysis showed it improved targeted antimicrobial adjustments and facilitated antibiotic de-escalation, suggesting FILMARRAY® may add value to antibiotic stewardship. Subsequent trials could substantiate this theoretical proposition. Chictr.org.cn, ChiCTR2100047213, registered 11 June 2021-prospectively registered, https://www.chictr.org.cn/showproj.html?proj=128024 . • FILMARRAY® molecular techniques, via semiquantitative analysis to identify potential pathogens, may contribute to reduce antibiotic usage and facilitate more targeted and appropriate antibiotic therapy in adult patients with lower respiratory tract infections. • Integrating FILMARRAY® into pediatric pneumonia care did not notably raise initial overall antibiotic modification rates. However, exploratory analysis showed it improved targeted antimicrobial adjustments and promoted antibiotic de-escalation, suggesting potential value for antibiotic stewardship.
Clinical relevance
In hospitalized children with infectious pneumonia, does adding the FILMARRAY® Pneumonia Panel (FAPP) to standard care increase the proportion of patients who undergo antibiotic changes within 72 hours compared with standard care alone? __SNAPSHOT__ {"studyDesign":"Single-center, open-label, parallel-group randomized controlled trial","setting":"Single center; country not explicitly reported in the abstract (enrollment December 2021–February 2023); likely China based on authorship and institutional context","sampleSize":"n=315 (intervention: 157, control: 158)","population":"Hospitalized children aged 28 days to 18 years diagnosed with infectious pneumonia","intervention":"FILMARRAY® Pneumonia Panel (FAPP) added to standard care","comparator":"Standard care only","primaryOutcome":"Proportion of patients with any antibiotic change within 72 hours of enrollment","followUp":"Not reported beyond the 72-hour primary endpoint window; duration of overall follow-up not reported","fundingSource":"Not reported"}
Key findings
The primary outcome — proportion of patients with any antibiotic change within 72 hours — did not differ significantly between the FAPP group and the control group (51.6% [81/157] vs. 49.4% [78/158]; P=0.693). FAPP detected pathogens in 86.6% of patients: 32.7% bacterial, 56.5% viral, and 10.9% atypical organisms; the authors note that this high detection rate may encompass colonizing organisms given the panel's enhanced sensitivity. Among pre-specified exploratory secondary outcomes, the FAPP group demonstrated significantly higher total frequency of antibiotic and antiviral agent changes based on pathogen results (47.8% [75/157] vs. 25.3% [40/158]; P<0.001) and a significantly greater proportion of patients with antibiotic de-escalation within 72 hours (14.6% [23/157] vs. 1.9% [3/158]; P<0.001). Absolute difference in de-escalation rate: 12.7 percentage points (calculated); NNT for de-escalation: approximately 8 patients (calculated). Additional secondary outcomes (e.g., clinical cure rates, length of stay, duration of antibiotic therapy, safety events) were not available in the abstract and are therefore not reported here.
Practice implications
This trial failed to demonstrate a statistically significant difference in its pre-specified primary endpoint — any antibiotic modification within 72 hours — between FAPP-guided and standard care. This is the central null result and must be the primary interpretive frame. The finding suggests that, in this population, the immediate impulse to change antibiotics was similarly high regardless of whether FAPP results were available, which may reflect prescriber behavior, the open-label design, or the complexity of interpreting a highly sensitive multiplex panel in pediatric pneumonia (where viral co-detection and colonization are common). The significant improvements in exploratory secondary outcomes — specifically targeted antimicrobial adjustments and antibiotic de-escalation — are hypothesis-generating and must be interpreted cautiously, as they were not the pre-specified primary endpoint and carry elevated risk of type I error given multiple comparisons. The de-escalation finding (14.6% vs. 1.9%; NNT≈8 [calculated]) is clinically plausible and noteworthy, but cannot be used to change practice without confirmatory data from a trial powered for this endpoint. Generalizability is limited by the single-center design, open-label nature, the likely Chinese inpatient context (predominantly community-acquired pneumonia in children), and the unknown degree to which an antimicrobial stewardship program was operational at the study site. Neonates under 28 days and immunocompromised children were not specifically addressed in the abstract. Only the abstract was available for this review; full-text data on secondary outcomes, adverse events, length of stay, and clinical cure rates could not be assessed. __LIMITATIONS__ Open-label design introduces significant performance and ascertainment bias — clinicians knew which arm patients were in, which directly affects antibiotic decision-making, the very behavior being measured.,Single-center enrollment limits generalizability and increases susceptibility to site-specific prescribing culture.,The trial was powered for the primary endpoint (antibiotic change within 72 hours); all secondary outcome analyses, including the de-escalation finding, are exploratory and not adjusted for multiplicity.,High FAPP positivity rate (86.6%) with acknowledged risk of detecting colonizing organisms rather than true pathogens creates an inherent interpretive challenge that may have diluted the stewardship signal.,The primary endpoint ('any antibiotic change') is a process measure and not a clinical outcome — it does not capture direction of change (escalation vs. de-escalation), appropriateness, or patient-important outcomes such as mortality, length of stay, or treatment failure.,The baseline antibiotic change rate in the control arm (49.4%) was high, suggesting active empirical prescribing adjustment even without FAPP, which may have reduced the detectable effect of the intervention.,Full-text data were not available for this review; duration of follow-up, safety outcomes, clinical cure rates, and full secondary outcome results cannot be independently verified.,Funding source is not reported, precluding assessment of potential commercial bias.,Enrollment during a specific seasonal window (December 2021–February 2023) may introduce pathogen-prevalence bias (winter respiratory season). __BOTTOM_LINE_CATEGORY__ promising_but_preliminary __BOTTOM_LINE__ In this single-center pediatric RCT, adding the FILMARRAY® Pneumonia Panel to standard care did not significantly increase the rate of antibiotic change within 72 hours (52% vs. 49%; P=0.693), failing its primary endpoint. Exploratory analyses suggested FAPP may facilitate antibiotic de-escalation (14.6% vs. 1.9%; NNT≈8 [calculated]), but these findings are hypothesis-generating only and require confirmation in adequately powered, multicenter trials with stewardship-supported protocols before influencing clinical practice.